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Abstract 
Lycopene is an important compound with an increasing industrial value. However, there is still no biotechnological 
process to obtain it. In this study, a semi‑continuous system for lycopene extraction from recombinant Escherichia 
coli BL21 cells is proposed. A two‑phase culture mode using organic solvents was found to maximize lycopene 
production through in situ extraction from cells. Within the reactor, three phases were formed during the process: an 
aqueous phase containing the recombinant E. coli, an interphase, and an organic phase. Lycopene was extracted from 
the cells to both the interphase and the organic phase and, consequently, thus enhancing its production. Maximum 
lycopene production (74.71 ± 3.74 mg L−1) was obtained for an octane‑aqueous culture system using the E. coli 
BL21LF strain, a process that doubled the level obtained in the control aqueous culture. Study of the interphase by 
transmission electron microscopy (TEM) showed the proteo‑lipidic nature and the high storage capacity of lyco‑
pene. Moreover, a cell viability test by flow cytometry (CF) after 24 h of culture indicated that 24 % of the population 
could be re‑used. Therefore, a batch series reactor was designed for semi‑continuous lycopene extraction. After five 
cycles of operation (120 h), lycopene production was similar to that obtained in the control aqueous medium. A final 
specific lycopene yield of up to 49.70 ± 2.48 mg g−1 was reached at 24 h, which represents to the highest titer to 
date. In conclusion, the aqueous‑organic semi‑continuous culture system proposed is the first designed for lycopene 
extraction, representing an important breakthrough in the development of a competitive biotechnological process 
for lycopene production and extraction.
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Introduction
Lycopene is a tetraterpenoid (C40) precursor of carot-
enoids. Traditionally, it was considered a colorant and a 
food additive, but new applications have been proposed 
for use as an antioxidant (Chasse et al. 2001) and anticar-
cinogen (Giovannucci et al. 2002; Rabi and Gupta 2008) 
and for preventing against cardiovascular diseases (Rao 
2002), hepatic fibro-genesis (Kitade et al. 2002) or human 
papillomavirus persistence (Sedjo et al. 2002). In spite of 
its great importance, most of lycopene is obtained from 
tomato, and no a competitive biotechnological exists 
process for its production.
In industry, methods based on metabolic engineer-
ing are the most profitable due to their high productiv-
ity and, consequently, the search for a biotechnological 
method for lycopene production is an important chal-
lenge for many researchers. In the last decade, many 
studies have been reported concerning lycopene pro-
duction by metabolic engineering, some of which are 
based on E. coli, the most important cell factory micro-
organism in biotechnology (Kim and Keasling 2001; 
Martin et  al. 2003; Alper et  al. 2006; Yuan et  al. 2006; 
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Rodriguez-Villalon et  al. 2008; Yoon et  al. 2008; Zhou 
et  al. 2012; Chen et  al. 2013). Recombinant E. coli are 
capable of biosynthesizing lycopene through either 
the mevalonate (MEP) or the non-mevalonate route. 
Although the E. coli possesses the genes of the non-
mevalonate route (or 2-C-methyl-d-erythritol 4-phos-
phate pathway) for isopentenyl pyrophosphate (IPP) 
synthesis, is still requires the following three enzymes, 
geranylgeranyl pyrophosphate (GGPP) synthase (crtE), 
phytoene synthase (crtB) and phytoene desaturase 
(crtI) to be able to synthesize lycopene. Therefore, a 
recombinant bacterium which contains these enzymes 
is necessary (Additional file  1: Figure S1). Previous 
works demonstrated that carotenoid production can 
be improved by increasing the amount of IPP and its 
isomer dimethylallyl pyrophosphate (DMAPP) amount 
available in the recombinant E. coli engineered (Jin 
and Stephanopoulos 2007; Zhou et  al. 2012; Zhang 
et  al. 2013). Besides to E. coli, carotenogenic micro-
organisms, such as Blakeslea trispona (Xu et  al. 2007) 
and the non-carotenogenic yeasts, Pichia pastoris 
(Araya-Garay et  al. 2012) and Saccharomyces cereve-
siae (Bahieldin et al. 2014), have been used to produce 
lycopene.
Despite the achievements made to date, there is still no 
competitive biotechnological method to compete with 
lycopene extraction from tomatoes. The main problems 
of these metabolic engineering processes are plasmid 
instability and the low capability to accumulate lycopene 
in the cytoplasmic membrane from non-carotenogenic 
organisms (Wang et  al. 2012). Hence, the in  situ recov-
ery of lycopene from a recombinant E. coli strain is the 
goal for achieving a competitive biotechnological pro-
cess. To our knowledge there are few studies concerning 
lycopene extraction from E. coli. It has been reported an 
in  situ process based on lycopene overproduction and 
recovery using octane and decane as extraction solvents 
(Yoon et  al. 2008). However, the lycopene percentage 
extracted was quite low. The partial digestion of bacte-
rial walls with lysozyme improved the system extractive 
capacity, although this digestion was quickly reverted as 
bacteria duplicated. In 2011, an in situ extraction process 
of retinoids from E. coli was reported (Jang et al. 2011), 
in which dodecane was used as extraction solvent, attain-
ing a 68-fold higher productivity than attained with the 
aqueous system.
Hence, the search for a competitive system concerning 
both lycopene production and extraction is of great inter-
est in the biotechnology field. In this paper, we propose 
the first semi-continuous system to produce and extract 
high amounts of lycopene employing a recombinant E. 
coli strain.
Materials and methods
Cell mass and specific growth rate
Cell mass was determined using a linear calibration curve 
relating optical density at 600 nm (OD600) and dry cell 
weight (R2 = 0.99). Cells were filtered and washed thor-
oughly with distilled water, and then dried at 130 °C for 
24  h to a constant weight using a thermobalance (Elec-
tronic Moisture Analyzer model MA35, Sartorius). The 
exponential growth phase was identified and the specific 
growth rate was determined for all culture strains cul-
tures (Sauer et al. 1999).
Transformation and culture conditions
Chemically competent E. coli K12 (BW25113) (Baba et al. 
2006) and BL21-Gold (DE3) (Agilent Technologies) cells 
were transformed with the pAC-Lyc plasmid, which con-
tained three genes of the lycopene pathway, crtE, crtB 
and crtI, and a chloramphenicol resistance gene, by heat 
shock at 42  °C. The resulting strains were called E. coli 
K12L and E. coli BL21L, respectively. Then, E. coli BL21L 
was made competent again and co-transformed with the 
pET-SIDF and pET-SIDFG plasmids, obtaining the strains 
E. coli BL21LF and E. coli BL21LG, respectively (Table 1). 
These plasmids contained the genes dxs, idi, ispD, ispF 
(pET-SIDF) and dxs, idi, ispD, ispF and ispG (pET-SIDFG) 
and an expression plasmid controlled by the inducible 
promoter T7. Besides, they showed ampicillin resistance. 
The plasmids pAC-Lyc, pET-SIDF and pET-SIDFG were 
kindly supplied by Prof. G. Stephanopoulos (Department 
of Chemical Engineering, Institute of Technology, Cam-
bridge, Massachusetts, EEUU) (Zhou et al. 2012).
Lycopene biosynthesis was carried out in triplicate in 
500  mL flasks containing 50  mL of MM9 medium with 
20 mM glucose or 40 mM glycerol using an orbital shak-
ing at 200 rpm and 28 °C. The culture medium was sup-
plemented with appropriate antibiotics (30  μg  mL−1 
chloramphenicol and/or 100 μg mL−1 ampicillin).
Lycopene extraction
Metabolically engineered E. coli cells were harvested by 
centrifugation at 10,000×g for 5 min at 4 °C. The cell pel-
let was resuspended in 1  mL of acetone and vigorously 
Table 1 Recombinant E. coli cells used in this study
Strains Plasmids Named in this study
pAC-Lyc pET-SIDF pET-SIDFG
E. coli K12 X E. coli K12L
E. coli BL21 X E. coli BL21L
X X E. coli BL21LF
X X E. coli BL21LG
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stirred for 10 min at 4  °C. The mixture was then centri-
fuged at 10,000×g for 10  min, and the acetone super-
natant was filtered through a 0.2 μm nylon sterile filter. 
Then, samples were lyophilized (Thermo Scientific Heto 
PowerDry) and the final extract was resuspended in 
0.1 mL of a 50:50 (v:v) mixture of A:B mobile phases for 
HPLC analysis. The lycopene extracted from the inter-
phase was treated using the same procedure. The organic 
solvent phase was filtered through a 0.2 μm nylon sterile 
filter and lyophilized.
Lycopene quantification by HPLC
The HPLC separation was performed on a Shi-
madzu HPLC equipped with a multi-channel 
pump (mod LC-20AD) and a DAD detector (mod 
SPD-M20A) with a Develosil® C30-UG-5 column 
(250 mm × 4.6 mm × 5 μm) from Phenomenex. Elution 
conditions were based on the chromatographic method 
developed by (Sander et  al. 1994) with modifications. 
Two mobile phases were used: phase A, composed of 
methanol and water (96:4, v:v) and phase B, tert-butyl 
methyl ether. The flow rate was 1.2  mL  min−1 and the 
injection volume 40  μL. The column was thermostated 
at 30  °C. The separation of carotenoid standards and 
extracts was carried out using a linear mobile phase 
gradient from 50:50 (volume ratio, A/B) to 37:63 (vol-
ume ratio, A/B) in 12 min; then the system was restored 
to its initial condition for 5  min. The concentrations of 
lycopene, 13-cis-lycopene and phytoene were calculated 
using response factors relative to the internal standard, 
β-apo-8-carotenal. Carotenoid identification was car-
ried out by comparing the retention times and absorp-
tion spectra characteristics (Additional file  1: Table S1) 
by reference to standards purchased from Sigma Aldrich. 
Detection was performed at 472  nm for lycopene and 
13-cis-lycopene and at 285 nm for phytoene (Additional 
file  1: Figure S2). Measurements obtained from cell 
extracts were compared to curves generated from stand-
ards (R2 = 0.99).
Transmission electron microscopy (TEM)
Escherichia coli BL21LF cells and interphase samples 
were fixed with 3 % glutaraldehyde for 30 min and pre-
pared as previously described (Huxley and Zubay 1960). 
The ultrathin sections were cut in a Reichert–Young 
ultramicrotom. Staining was carried out with 2  % ura-
nyl acetate. Sections were then examined by using a Carl 
Zeiss EM 10 C electron microscope.
Flow cytometry (FCM)
Samples were run by flow cytometry (FCM) in a Becton–
Dickinson FASort model equipped with an argon laser 
for excitation at 488  nm and 15  mW and filters at 525 
and 630  nm. Samples were adjusted to an event rate of 
800–2000 cells s−1 and a total of 10,000 events were reg-
istered per sample. To determine cell viability by FCM, 
double staining was performed accordingly to (Hewitt 
et al. 1999). PI and BOX were used for viability studies on 
living cells. The FCM probe fluoresceinpropidium iodide 
(PI) was purchased from Sigma–Aldrich, while bis-(1,3-
dibutylbarbituric acid) trimethine oxonol (Bis-oxonol, 
BOX) was purchased from Molecular Probes Inc. Stained 
cells were diluted in phosphate buffered saline solution 
pH 7.2 (PBS). FALS and RALS values allowed cell debris 
discrimination and a total of 10,000 events were used for 
statistical data analysis.
Heat stressed cells treated at 60 °C for 30 min and expo-
nentially growing cells were used as positive and negative 
controls, respectively. The green fluorescence channel 
for BOX-stained cells (X-axis) was plotted versus the red 
fluorescence channel for PI stained cells (Y-axis). Flow 




Recombinant E. coli BL21LF and E. coli BL21LG (Table 1) 
were cultivated in MM9 medium containing 20 mM glu-
cose as carbon source with 200 rpm orbital shaking and 
28  °C. When the cultures reached 0.5 OD, the IPTG 
inductor was added at concentrations ranging from 0 to 
1.0 mM. Samples were taken from each culture for lyco-
pene extraction at 24  h, when the lycopene production 
was maximum. As shown in Fig.  1, a positive correla-
tion between lycopene production and inductor concen-
tration was noted for the two recombinant E. coli BL21 
strains. Based on these results, the IPTG concentration 
selected was 0.1 and 0.4  mM for E. coli BL21LF and E. 
coli BL21LG, respectively.
Optimization of culture conditions
In order to determine the optimal culture conditions, 
besides lycopene, the 13-cis-lycopene and phytoene con-
tent were quantified, the first since it is a lycopene isomer 
and is often produced by lycopene oxidative degrada-
tion (Chasse et  al. 2001) and the second, as the precur-
sor of lycopene. To select a carbon source for lycopene 
production, 50 mL batch cultures for the whole recombi-
nant E. coli strains (K12L, BL21L, BL21LF and BL21LG) 
were carried out using either 40 mM glycerol or 20 mM 
glucose (Additional file  1: Figure S3). All cultures were 
made by orbital shaking at 200 rpm and 28 °C, which is 
the optimal temperature for lycopene biosynthesis (Kim 
et al. 2011). The biomass, lycopene, 13-cis-lycopene and 
phytoene content were determined at 24 h. The specific 
growth rate was also calculated for each culture (Table 2).
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Glycerol cultures exhibited the highest lycopene pro-
duction, whereas glucose cultures showed the highest 
cell mass and specific growth rate. In all cultures, the 
phytoene concentration was very low compared with 
lycopene (lower than 5  %), demonstrating a optimal 
expression of pAC-Lyc plasmid (Rodriguez-Villalon et al. 
2008). The maximum lycopene content was obtained 
from the Ecoli BL21LF strain when glycerol was used as 
carbon source (Fig.  2). Therefore, glycerol was selected 
as carbon source for lycopene production with E. coli 
BL21LF in all subsequent studies.
The effect of key fermentation control parameters, such 
as shaking speed and light, on the production of lycopene 
were also tested. In the whole set of cultures exposed to 
light, the concentration of 13-cis-lycopene was very low 
compared with lycopene (lower than 8  %). When these 
same cultures were grown in darkness, no differences were 
detected for the isomer concentration, thus this additional 
precaution was discarded (data not shown). Orbital shak-
ing speed was investigated as a putative bioreactor param-
eter responsible for controlling dissolved oxygen content 
and maximum cell density. Batch cultures in 500  mL 
flasks with 50 mL MM 9 medium were carried out at three 
orbital shaking speeds: 100, 200 and 400  rpm. However, 
there were no differences in lycopene production.
Lycopene production was evaluated in detail using glyc-
erol as carbon source and the selected E. coli BL21LF in 
50  mL batch culture and with 200  rpm orbital shaking at 
28 °C. For this purpose, three samples were taken at differ-
ent times up to 24 h (Fig. 3). Lycopene production started 
during the exponential growth phase, and the maximum 
lycopene concentration was reached in the stationary phase, 
since it is a secondary metabolite biomass dependent.
Increase of lycopene production via in situ extraction 
in organic-aqueous culture systems
The effect of organic solvents on cell growth and lyco-
pene production in metabolically engineered E. coli 
Fig. 1 Lycopene production at different IPTG concentrations after 
24 h in glucose culture. Grey bars and solid bars represent the results 
obtained using E. coli BL21F and the E. coli BL21G, respectively. Data 
represent the means and standard deviations from three separate 
experiments
Table 2 Effect of  carbon source on  cell growth (OD), lyco-
pene production and  specific growth rate (μmax) in  the E. 
coli aqueous cultures
Data represent the means and standard deviations from three separate 
experiments
Carbon source OD (600 nm) Lycopene (mg L−1) μmax (h
−1)
Glucose
 E. coli K12L 3.56 ± 0.07 16.18 ± 0.81 0.33 ± 0.03
 E. coli BL21L 3.86 ± 0.04 11.51 ± 0.52 0.43 ± 0.01
 E. coli BL21LF 4.27 ± 0.04 27.51 ± 1.35 0.43 ± 0.02
 E. coli BL21LG 3.29 ± 0.17 21.15 ± 1.01 0.35 ± 0.04
Glycerol
 E. coli K12L 3.61 ± 0.15 20.88 ± 1.04 0.27 ± 0.01
 E. coli BL21L 3.95 ± 0.24 14.84 ± 0.74 0.30 ± 0.04
 E. coli BL21LF 2.79 ± 0.04 37.56 ± 1.41 0.31 ± 0.01
 E. coli BL21LG 1.55 ± 0.06 27.28 ± 0.81 0.28 ± 0.06
Fig. 2 Comparison between glucose (solid bars) and glycerol (grey 
bars) as main carbon sources for lycopene production after 24 h 
using the recombinant E. coli strains. Data represent the means and 
standard deviations from three separate experiments
Page 5 of 11Gallego‑Jara et al. AMB Expr  (2015) 5:65 
BL21LF was investigated in batch cultures. Organic sol-
vents for lycopene extraction were selected as a function 
of the log P solvent, which ranged from 3.76, 4.27, 4.78, 
5.8 to 6.31 for heptane, hexane, octane, decane, undecane 
and dodecane, respectively.
Batch cultures were performed using an organic:culture 
broth volume ratio of 1:5 (v/v) for the whole set of the 
50 mL cultures. Organic solvent was added when the bio-
mass reached 0.5 OD, in order not to affect cell growth. 
Hexane and heptane were rejected; hexane due to its 
high volatility and heptane as a consequence of its toxic-
ity to cells. An aqueous culture without organic solvent 
was used as control system and the resulting lycopene 
production (37.56 ± 1.41 mg L−1) was used to normalize 
lycopene biosynthesis.
In all the aqueous-organic systems, three phases were vis-
ible after 24 h in the presence of organic solvent: an aque-
ous phase containing the E. coli BL21LF cells, an interphase 
and the organic phase. This tri-phasic culture system and 
normalized lycopene production at 24 h for all the organic-
aqueous culture systems can be seen in Fig. 4A, B. Inter-
estingly, lycopene production greatly increased with the 
addition of organic solvent except for undecane, although 
the lycopene production profile presented a negative cor-
relation with the solvent log P. Final lycopene production 
after 24 h was 198.9, 148.6 and 115.97 % for octane, decane 
and dodecane, respectively, with respect to the control 
aqueous culture. In these organic-aqueous culture systems, 
lycopene was extracted from the cells to the interphase 
and the organic phase, which greatly enhanced produc-
tion. Maximum lycopene production was obtained for 
the octane-aqueous system reaching 74.71 ± 3.74 mg L−1 
(198.9 %). This lycopene production was distributed among 
the three phases formed: 12.24 ± 0.61 mg L−1 into E. coli 
BL21LF cells of the aqueous phase, 57.14 ± 2.85 mg L−1 in 
the interphase and 5.32 ± 0.24 mg L−1 in the octane phase. 
As regards to the cell density, the OD at 600  nm of the 
aqueous media was similar to the aqueous-organic systems 
at 24 h, around 4.00 ± 0.35. The E. coli BL21LF growth cul-
ture is shown in Additional file 1: Figure S4.
In order to study the physicochemical properties of the 
interphase formed in the aqueous-organic systems, trans-
mission electron microscopy (TEM) was used (Fig. 5A). 
Spherical particles of homogeneous size ranging from 15 
to 20 nm were observed, demonstrating its proteo-lipidic 
nature and with high lycopene storage capacity of these 
particles, representing 76.5  % (57.14 ±  2.85  mg  L−1) of 
the total culture content. TEM was also used to visu-
alize E. coli BL21LF cells after 24  h (Fig.  5B–F). Pic-
tures b and c show E. coli BL21LF cells in the aqueous 
medium, whereas d and e show E. coli BL21F cell within 
the octane-aqueous culture system, and f shows E. coli 
BL21LF in the heptane-aqueous culture system. As 
depicted, E. coli BL21LF cell growth in aqueous media 
entirely maintained the outer membrane structure, and 
even the lipid double layer could be observed. But when 
the octane-aqueous culture system was employed, the 
cells partially lost the structural integrity of their outer 
membrane. This explains the high extractive capacity of 
octane for lycopene and the proteo-lipidic interphase 
formation. Cells completely lost their structural integrity 
when heptane was used.
Fig. 3 Specific lycopene content (grey bars) and biomass (filled circle) of recombinant E. coli BL21LF in 50 mL batch culture with 40 mM glycerol, 
200 rpm and 28 °C. Data represent the means and standard deviations from three separate experiments
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To determine cell viability, flow cytometry (FCM) using 
scattered light was chosen. Two fluorochromes were 
employed simultaneously: bis-(1,3-dibutylbarbituric 
acid) trimethine oxonol (Bis-oxonol, BOX) and propid-
ium iodide (PI). BOX is a lipophilic anionic compound, 
which accumulates intracellularly when the cytoplasmic 
membrane is depolarised, while PI binds to DNA, but 
cannot cross an intact cytoplasmic membrane (Hewitt 
et  al. 1999). Cell analysis by FCM demonstrated that, 
during a fed-batch culture in an aqueous-octane system, 
there was a gradual change in the physiological state of E. 
coli BL21LF. From samples taken at 24 h, three main sub-
populations of cells were observed (Fig. 6). These popula-
tions corresponded to healthy unstained cells (A3); cells 
with a depolarised cytoplasmic membrane (A4), stained 
with BOX; and dead cells with permeabilised mem-
branes, namely cells stained with both PI and BOX (A2). 
From Fig.  6, the cell number and the percentage within 
Fig. 4 A Tri‑phasic culture system for aqueous‑organic systems. b Interphase. c E. coli BL21LF cells. Both phases were orange by the presence of 
lycopene. B Lycopene production normalized at 24 h for the organic‑aqueous culture systems with E. coli BL21LF, distributed among three phases: 
aqueous phase containing E. coli BL21LF cells (solid bars), interphase (grey bars) and organic phase (open bars)
Fig. 5 A Transmission electron microscopy of the interphase of the octane‑aqueous culture prepared with negative staining. Transmission electron 
microscopy of E. coli BL21LF: B and C in aqueous media, D and E in aqueous‑octane culture system and F in aqueous‑heptane culture system. 
Amplifications were ×40,000 for B, C and D and ×100,000 for E and F
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each quadrant was determined using the CF software. 
The results are shown in Table 3. Cells from a microbial 
culture can be grouped according to their different meta-
bolic states and/or extent of cell integrity: (a) intact and 
metabolically active cells, showing growth capacity, (b) 
depolarized cells, unable to maintain their intact mem-
brane potential, but that can be recovered temporarily 
(Cánovas et al. 2007), (c) and dead cells with permeabi-
lised and depolarised membrane (Hewitt et al. 1999). The 
aqueous-octane culture system E. coli BL21LF after 24 h, 
resulted in an 11.5  % of healthy unstained cells and a 
13.24 % of deporalised but recoverable BOX stained cells. 
Therefore, both of them (24.74 %) can be considered via-
ble for the continuous production of lycopene.
Aqueous-octane culture system for in situ extraction 
and semi-continuous lycopene production
Maximum lycopene production was obtained from the 
octane-aqueous system (1:5 volume ratio) after 24  h of 
culture, when cell growth had ceased and the lycopene 
content was distributed among the three phases. From 
these results, a series batch reactor was designed for 
lycopene extraction, as depicted in Fig. 7a. The aqueous-
octane culture system was maintained in operation for 
24 h, then the volume of the aqueous phase correspond-
ing to a final 0.05 OD was used as the inoculum for a 
second batch reactor (taking into account the viable cells 
fraction). This process was repeated 5 times.
Figure  7b displays the lycopene production distrib-
uted in each phase and cycle. The lycopene produced 
in the first cycle was used to normalize the lycopene 
content of the remaining cycles. In the first three, 
the lycopene production was 74.71  ±  3.74  mg  L−1, 
51.03 ±  2.51  mg  L−1 and 46.45 ±  2.13  mg  L−1, respec-
tively, all of them higher than that obtained in the aque-
ous medium (37.56 ± 1.41 mg L−1). Lycopene production 
was 29.01 ±  1.52  mg  L−1 and 36.96 ±  1.82  mg  L−1 for 
the fourth and fifth cycle, respectively, similar to that 
obtained in the aqueous medium. The biomass reached 
in each batch reactor was similar, about 3.82 ± 0.35 OD, 
although production deceased with each cycle.
Discussion
Metabolic engineering to increase lycopene production 
in E. coli has previously focused on overexpression of the 
several key isoprenoid genes (Alper et  al. 2005). Hence, 
the first part of this study was focused on the optimiza-
tion of both the recombinant E. coli strain and culture 
conditions. When the recombinant E. coli BL21LF and 
E. coli BL21G strains were used in combination with the 
IPTG-induced, lycopene production increased, although 
excessive IPTG concentration reduced lycopene biosyn-
thesis (Fig.  1). This finding is consistent with previous 
observations of the induction inhibitory effects of lyco-
pene production (Kim and Keasling 2001; Rodriguez-Vil-
lalon et al. 2008; Yoon et al. 2008) since, a high induction 
could cause a shortage of the available precursors for 
the essential metabolic roles. The IPTG concentrations 
selected were 0.1 and 0.4 mM for E. coli BL21LF and E. 
coli BL21LG, respectively. The lower lycopene production 
obtained with E. coli BL21LG was probably due to the 
high energy cost of the extra ispG gene overexpression, 
which encodes the HDS protein. It has been revealed that 
ispG gene basal expression is higher than the expression 
of other of isoprenoid genes under normal growth condi-
tions (Yuan et  al. 2006). Accordingly, a high multi-copy 
expression vector may cause a metabolic imbalance. In 
addition, the HDS enzyme (4-hydroxy-2-methyl-2-bute-
nyl 4-diphosphate synthase) flavodoxin reductase and 
NADPH dependent metalloprotein, (Rohdich et al. 2003; 
Seemann et al. 2006) involve an extra expense of reduc-
ing power to carry out their catalytic functions (Hunter 
2007). These assumptions could explain the E. coli 
BL21LG strain delay metabolic.
Fig. 6 Flow cytometry (FCM) of the E. coli BL21LF strains in an 
aqueous‑octane culture system. Green fluorescence of cells (axis 
X) due to BOX is plotted versus red fluorescence (axis Y) due to PI. 
Samples were taken from the batch reactor at 24 h
Table 3 Cells number and  percentage in  each one of  the 
FCM windows
Cell debris was identified on the basis of the FALS and RALS values
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In previous studies, glycerol and glucose were com-
pared as carbon sources for secondary metabolite pro-
duction, glycerol being seen as a better carbon source 
than glucose (Lee 1996; Martin et  al. 2001; Yoon et  al. 
2009). Glycerol reduces cell growth, but stimulates 
metabolite production (Fang and Demain 1997).
On the other hand, the recombinant E. coli BL21 and 
K12 strains showed differences in lycopene production, 
the latter producing 1.4-fold more than the E. coli BL21L 
strain (Fig. 2). Significant differences have been demon-
strated at gene transcription and metabolomic profile 
levels between both E. coli strains (Alper et al. 2006). In 
addition, the outer membranes of E. coli K12 and E. coli 
BL21 also show differences in lipoprotein and lipid com-
position, which may influence cell envelope permeabil-
ity and integrity. These differences could affect potential 
lycopene accumulation (Yoon et  al. 2012; Marisch et  al. 
2013).
The maximum lycopene production and specific 
lycopene production were 37.56  ±  1.41  mg  L−1 and 
25.34 ± 1.2 mg g cell−1, respectively, which was obtained 
during stationary growth phase using E. coli BL21LF in 
40  mM glycerol and 0.1  mM IPTG (Fig.  2). This pro-
duction is excellent compared with the lycopene lev-
els previously reported. Stephanopoulos group’s (2006) 
created a triple knockout strain, ΔgdhA ΔaceE ΔfdhF, 
which exhibited a lycopene production of 8.15  mg  g 
cell−1 (Alper et al. 2006). Kin et al. (2011) used a meta-
bolically engineered E. coli strain, reporting a lycopene 
production of 32  mg  g cell−1 in fed-batch cultures with 
glycerol supplemented with glucose as auxiliary carbon 
source. Recently, a higher level of lycopene production 
(33.43  mg  g cell−1) was attained by native appY pro-
moter replacement of a T5 promoter, and the deletion 
of the iclR gene in E. coli CBW 12241 (Chen et al. 2013). 
High lycopene production was also achieved (18.49 mg g 
Fig. 7 a Series batch reactor for lycopene over‑production using E. coli BL21LF in an aqueous‑octane culture system. b Normalized lycopene 
production distributed within each phase for each cycle: aqueous phase containing E. coli BL21LF cells (solid bars), interphase (grey bars) and organic 
phase (light grey bars), and biomass (filled circle). Data represent the means and standard deviations from three separate experiments
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cell−1) using a CRP engineering strategy (Huang et  al. 
2015).
One of the main limitations of biotechnological lyco-
pene production is the fact that it is stored as an intra-
cellular product in the membrane (Fraser and Sandmann 
1992). Therefore, special must be taken into account to 
identify the optimal parameters for continuous lycopene 
production. It has been assumed that the upper limit for 
the carotenoid production in a non-carotenogenic E. 
coli is around 2 mg g cell−1 due to the limited lipophilic 
carotenoid storage capacity of the membrane (Albre-
cht et  al. 1999; Sandmann 2001). Hence, a new strategy 
is needed to overcome the lycopene accumulation bar-
rier. Optimal parameters must be determined in order 
to promote lycopene production during both the expo-
nential and stationary phase, while stimulating in  situ 
extraction to prevent accumulation in the cell membrane. 
Moreover, when the whole cells are employed as bio-
catalyst, productivity may decrease due to end-product 
inhibition or accumulation: however, if the product is 
continuously removed by a solvent phase, an increase in 
activity/productivity can be attained. To achieve this aim, 
a two-phase culture system using an organic solvent was 
proposed to maximize the lycopene production through 
in situ extraction from the cells. Few studies using organic 
solvents for terpenes extraction have been published. It 
has been reported a two-phase culture system with dode-
cane for retinoids extraction using a metabolically engi-
neered E. coli (Jang et  al. 2011). In a previous report, a 
two-phase culture system with decane and 0.1 % (w v−1) 
Span 20 was successfully applied for lycopene produc-
tion (9.6 ± 1.0 mg g−1) (Yoon et al. 2008). However, lyco-
pene was inefficiently extracted from the recombinant E. 
coli strain without partial digestion of the cell wall with 
lysozyme. The authors used E. coli spheroplasts in order 
to increase the extraction, but their instability reduced 
the possibility of designing a continuous system.
Another aspect to consider in a biphasic system is the 
organic solvent toxicity toward microorganisms. This 
toxicity depends on its inherent toxicity and the intrin-
sic tolerance of the bacterial species and strains (Ramos 
et al. 2002). The toxicity of a solvent correlates with the 
logarithm of its partition coefficient in n-octanol and 
water (log P), meaning that, organic solvents with a 
log P of between 1.5 and 4.0 are toxic for microorgan-
isms. Six organic solvents were selected for lycopene 
extraction as a function of the log P, ranging from 3.76 
to 6.31. In all aqueous-organic systems tested in this 
study three phases were formed after 2  h of culture: an 
aqueous phase containing cells, an interphase and an 
organic phase (Fig.  4A). Lycopene was removed from 
the cells to the interphase and the organic phase, thus 
enhancing production. Maximum lycopene produc-
tion was obtained from octane-aqueous systems (5:1, v 
v−1) (74.71 ± 3.74 mg L−1 or 49.70 ± 2.48 mg g cell−1), 
a 2-fold improvement over that attained in aqueous cul-
ture. This production was also much higher than that 
obtained from tomato, 0.42 mg g−1, which suggest it is a 
promising strategy for its industrial production (Sharma 
and Le Maguer 1996). This lycopene production rate is, 
to our knowledge, the highest reported in the literature 
to date. Moreover, the proteo-lipidic nature of the inter-
phase demonstrated by TEM (Fig.  5A), showed a high 
lycopene storage capacity of 76.5 % (57.15 ± 2.86 mg L−1) 
with respect to the total production of lycopene in aque-
ous-octane systems (Fig. 4B). This interface was formed 
from partial outer membrane disintegration, while cells 
with structural integrity were found in the aqueous-
octane systems after 24 h (Fig. 5D, E). Additionally, flow 
cytometry analysis of E. coli BL21LF cells showed a sig-
nificant percentage (24.74  %) of viable and cultivatable 
cells for continuous lycopene production (Fig. 6; Table 3). 
From these results, a series batch reactor for semi-con-
tinuous lycopene extraction was designed (Fig.  7a). The 
biomass reached was similar for the all cycles, although 
lycopene production decreased with each of cycle. The 
results further support the idea that cell depolarisation 
indicates a decline in cell functionality due to energy 
depletion, but does not involve cell death. Besides, lyco-
pene accumulation in the cell membrane seems to affect 
lycopene biosynthesis, since the amount of lycopene 
extracted from cells to the interphase and the organic 
phase decreased in each cycle. Nevertheless, the lyco-
pene production obtained from the fifth cycle (120  h) 
was 36.96 ± 1.82 mg L−1, similar to that obtained in the 
aqueous medium (Fig. 7b).
In this study, semi-continuous lycopene overproduc-
tion and in  situ extraction using a metabolically engi-
neered E. coli strain is attained for the first time with an 
octane-aqueous culture system (1:5 volume ratio). In the 
future, we hope these findings will be useful for industry 
and constitute an important step forward in the develop-
ment of a competitive biotechnological lycopene produc-
tion system.
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